Pharos iBio is a clinical stage biotech company that develops novel drug for rare and refractory diseases using AI(Artificial Intelligence)-based new drug discovery platform, “Chemiverse”. The Chemiverse Platform consists 9 modules including “Deep RECOM” and “ChemGEN” to achieve “Best Target and Best Chemical”. It is the company’s proprietary platform with >240M big data and deep-learning algorithms to support entire drug discovery process from Target ID to Drug Candidate. The company accelerate the drug development through Open Innovation for the optimization of the drugs. PHI-101 has been derived from Pharos iBio’s drug discovery and development platform making the drug optimization and exploring new indications. The Phase I clinical trials of PHI-101 for AML and ovarian cancer are ongoing.
The company seeks for partners who is willing together for further developments of the drugs or collaborations for the novel drug discovery and optimization.
The company seeks for partners who is willing together for further developments of the drugs or collaborations for the novel drug discovery and optimization.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PHI-101
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
